Nuclear Medicine - Global Market Outlook (2017-2026)

September 2018 | 168 pages | ID: N7BD82EC97BEN
Stratistics Market Research Consulting

Abstracts

According to Stratistics MRC, the Global Nuclear Medicine is accounted for $3.50 billion in 2017 and is expected to reach $6.50 billion by 2026 growing at a CAGR of 7.1% during the forecast period. Factors such as growing demand for early & precise diagnostic methods, increasing incidence of cancer and cardiovascular disorders and huge demand for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging are driving the market growth. However, supply deficiency, reimbursement hurdles for the manufacturer and high capital investment are restricting the growth of the growth. Moreover, rising economies, upcoming radioisotopes and increasing usage across neurological applications are providing ample opportunities for the market growth.

Nuclear medicines are used for both diagnostic and therapeutic uses and there are more than 30 specific radiopharmaceuticals used by medical practitioners. Nuclear medicine comes under the field of molecular imaging, which occupy the use of very little amount of radioactive material to detect and treat disease Several forms of nuclear medicines are required in treating cancer, neurological disorders, gastrointestinal and other diseases.

On the basis of application, therapeutic segment witnessed steady growth due to the introduction of advanced protective measures and growing awareness regarding the therapeutic procedures. By geography, North America is dominating the market during the forecasting period owing to increasing aging population, technological advancements and the presence of favorable reimbursement policies in this region.

Some of the key players in the Nuclear Medicine Market include Bayer AG, Medtronic, plc, General Electric Co., Cardinal Health, Inc., IBA Group, BWX Technologies, Australian Nuclear Science & Technology Organization (ANSTO), Mallinckrodt plc., Eckert & Ziegler Group, Lantheus Medical Imaging, Inc., Jubilant Life Sciences, Eczacibasi-Monrol Nuclear Products, Curium, Bracco Imaging S.p.A and NTP Radioisotopes SOC Ltd.

Products Covered:

• Therapeutic
• Diagnostic

Applications Covered:

• Therapeutic Applications
• Diagnostic Applications

End Users Covered:

• Research institutes
• Hospitals and Diagnostic centers

Regions Covered:

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• UK
• Italy
• France
• Spain
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia
• New Zealand
• South Korea
• Rest of Asia Pacific
• South America
• Argentina
• Brazil
• Chile
• Rest of South America
• Middle East & Africa
• Saudi Arabia
• UAE
• Qatar
• South Africa
• Rest of Middle East & Africa

WHAT OUR REPORT OFFERS:

• Market share assessments for the regional and country level segments
• Market share analysis of the top industry players
• Strategic recommendations for the new entrants
• Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
  2.4.1 Data Mining
  2.4.2 Data Analysis
  2.4.3 Data Validation
  2.4.4 Research Approach
2.5 Research Sources
  2.5.1 Primary Research Sources
  2.5.2 Secondary Research Sources
  2.5.3 Assumptions

3 MARKET TREND ANALYSIS

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Futuristic Market Scenario

4 PORTERS FIVE FORCE ANALYSIS

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 GLOBAL NUCLEAR MEDICINE MARKET, BY PRODUCT

5.1 Introduction
5.2 Therapeutic
  5.2.1 Brachytherapy
    5.2.1.1 Iodine-125
    5.2.1.2 Iridium-192
    5.2.1.3 Cesium-131
    5.2.1.4 Palladium-103
    5.2.1.5 Other Brachytherapies
  5.2.2 Beta emitters
    5.2.2.1 Lu-117
    5.2.2.2 Iodine-131
    5.2.2.3 Samarium-153
    5.2.2.4 Yttrium-90
    5.2.2.5 Rhenium 186/188
    5.2.2.6 Strontium
    5.2.2.7 Other beta emitters
  5.2.3 Alpha emitters
    5.2.3.1 RA-223
    5.2.3.2 Other alpha emitters
5.3 Diagnostic
  5.3.1 Positron Emission Tomography (PET)
    5.3.1.1 RB-82
    5.3.1.2 F-18
    5.3.1.3 Other PET products
  5.3.2 Single Photon Emission Computed Tomography (SPECT)
    5.3.2.1 TL-201
    5.3.2.2 TC-99m
    5.3.2.3 GA-67
    5.3.2.4 Other SPECT products

6 GLOBAL NUCLEAR MEDICINE MARKET, BY APPLICATION

6.1 Introduction
6.2 Therapeutic
  6.2.1 Endocrine Tumors
  6.2.2 Lymphoma
  6.2.3 Bone Metastasis
  6.2.4 Thyroid
  6.2.5 Other Therapeutic Applications
6.3 Diagnostic
  6.3.1 Thyroid
  6.3.2 Neurology
  6.3.3 Lymphoma
  6.3.4 Cardiology
  6.3.5 Oncology
  6.3.6 Other Diagnostics

7 GLOBAL NUCLEAR MEDICINE MARKET, BY END USER

7.1 Introduction
7.2 Research institutes
7.3 Hospitals and diagnostic centers

8 GLOBAL NUCLEAR MEDICINE MARKET, BY GEOGRAPHY

8.1 Introduction
8.2 North America
  8.2.1 US
  8.2.2 Canada
  8.2.3 Mexico
8.3 Europe
  8.3.1 Germany
  8.3.2 UK
  8.3.3 Italy
  8.3.4 France
  8.3.5 Spain
  8.3.6 Rest of Europe
8.4 Asia Pacific
  8.4.1 Japan
  8.4.2 China
  8.4.3 India
  8.4.4 Australia
  8.4.5 New Zealand
  8.4.6 South Korea
  8.4.7 Rest of Asia Pacific
8.5 South America
  8.5.1 Argentina
  8.5.2 Brazil
  8.5.3 Chile
  8.5.4 Rest of South America
8.6 Middle East & Africa
  8.6.1 Saudi Arabia
  8.6.2 UAE
  8.6.3 Qatar
  8.6.4 South Africa
  8.6.5 Rest of Middle East & Africa

9 KEY DEVELOPMENTS

9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 COMPANY PROFILING

10.1 Bayer AG
10.2 Medtronic, plc
10.3 General Electric Co.
10.4 Cardinal Health, Inc.
10.5 IBA Group
10.6 BWX Technologies
10.7 Australian Nuclear Science & Technology Organization (ANSTO)
10.8 Mallinckrodt plc.
10.9 Eckert & Ziegler Group
10.10 Lantheus Medical Imaging, Inc.
10.11 Jubilant Life Sciences
10.12 Eczacibasi-Monrol Nuclear Products
10.13 Curium
10.14 Bracco Imaging S.p.A
10.15 NTP Radioisotopes SOC Ltd.

12. LIST OF TABLES

Table 1 Global Nuclear Medicine Market Outlook, By Region (2016-2026) (US $MN)
Table 2 Global Nuclear Medicine Market Outlook, By Product (2016-2026) (US $MN)
Table 3 Global Nuclear Medicine Market Outlook, By Therapeutic (2016-2026) (US $MN)
Table 4 Global Nuclear Medicine Market Outlook, By Brachytherapy (2016-2026) (US $MN)
Table 5 Global Nuclear Medicine Market Outlook, By Beta emitters (2016-2026) (US $MN)
Table 6 Global Nuclear Medicine Market Outlook, By Alpha emitters (2016-2026) (US $MN)
Table 7 Global Nuclear Medicine Market Outlook, By Diagnostic (2016-2026) (US $MN)
Table 8 Global Nuclear Medicine Market Outlook, By PET (2016-2026) (US $MN)
Table 9 Global Nuclear Medicine Market Outlook, By SPECT (2016-2026) (US $MN)
Table 10 Global Nuclear Medicine Market Outlook, By Application (2016-2026) (US $MN)
Table 11 Global Nuclear Medicine Market Outlook, By Therapeutic (2016-2026) (US $MN)
Table 12 Global Nuclear Medicine Market Outlook, By Endocrine Tumors (2016-2026) (US $MN)
Table 13 Global Nuclear Medicine Market Outlook, By Lymphoma (2016-2026) (US $MN)
Table 14 Global Nuclear Medicine Market Outlook, By Bone Metastasis (2016-2026) (US $MN)
Table 15 Global Nuclear Medicine Market Outlook, By Thyroid (2016-2026) (US $MN)
Table 16 Global Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2016-2026) (US $MN)
Table 17 Global Nuclear Medicine Market Outlook, By Diagnostic (2016-2026) (US $MN)
Table 18 Global Nuclear Medicine Market Outlook, By Thyroid (2016-2026) (US $MN)
Table 19 Global Nuclear Medicine Market Outlook, By Neurology (2016-2026) (US $MN)
Table 20 Global Nuclear Medicine Market Outlook, By Lymphoma (2016-2026) (US $MN)
Table 21 Global Nuclear Medicine Market Outlook, By Cardiology (2016-2026) (US $MN)
Table 22 Global Nuclear Medicine Market Outlook, By Oncology (2016-2026) (US $MN)
Table 23 Global Nuclear Medicine Market Outlook, By Other Diagnostics (2016-2026) (US $MN)
Table 24 Global Nuclear Medicine Market Outlook, By End User (2016-2026) (US $MN)
Table 25 Global Nuclear Medicine Market Outlook, By Research institutes (2016-2026) (US $MN)
Table 26 Global Nuclear Medicine Market Outlook, By Hospitals and diagnostic centers (2016-2026) (US $MN)
Table 27 North America Nuclear Medicine Market Outlook, By Country (2016-2026) (US $MN)
Table 28 North America Nuclear Medicine Market Outlook, By Product (2016-2026) (US $MN)
Table 29 North America Nuclear Medicine Market Outlook, By Therapeutic (2016-2026) (US $MN)
Table 30 North America Nuclear Medicine Market Outlook, By Brachytherapy (2016-2026) (US $MN)
Table 31 North America Nuclear Medicine Market Outlook, By Beta emitters (2016-2026) (US $MN)
Table 32 North America Nuclear Medicine Market Outlook, By Alpha emitters (2016-2026) (US $MN)
Table 33 North America Nuclear Medicine Market Outlook, By Diagnostic (2016-2026) (US $MN)
Table 34 North America Nuclear Medicine Market Outlook, By PET (2016-2026) (US $MN)
Table 35 North America Nuclear Medicine Market Outlook, By SPECT (2016-2026) (US $MN)
Table 36 North America Nuclear Medicine Market Outlook, By Application (2016-2026) (US $MN)
Table 37 North America Nuclear Medicine Market Outlook, By Therapeutic (2016-2026) (US $MN)
Table 38 North America Nuclear Medicine Market Outlook, By Endocrine Tumors (2016-2026) (US $MN)
Table 39 North America Nuclear Medicine Market Outlook, By Lymphoma (2016-2026) (US $MN)
Table 40 North America Nuclear Medicine Market Outlook, By Bone Metastasis (2016-2026) (US $MN)
Table 41 North America Nuclear Medicine Market Outlook, By Thyroid (2016-2026) (US $MN)
Table 42 North America Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2016-2026) (US $MN)
Table 43 North America Nuclear Medicine Market Outlook, By Diagnostic (2016-2026) (US $MN)
Table 44 North America Nuclear Medicine Market Outlook, By Thyroid (2016-2026) (US $MN)
Table 45 North America Nuclear Medicine Market Outlook, By Neurology (2016-2026) (US $MN)
Table 46 North America Nuclear Medicine Market Outlook, By Lymphoma (2016-2026) (US $MN)
Table 47 North America Nuclear Medicine Market Outlook, By Cardiology (2016-2026) (US $MN)
Table 48 North America Nuclear Medicine Market Outlook, By Oncology (2016-2026) (US $MN)
Table 49 North America Nuclear Medicine Market Outlook, By Other Diagnostics (2016-2026) (US $MN)
Table 50 North America Nuclear Medicine Market Outlook, By End User (2016-2026) (US $MN)
Table 51 North America Nuclear Medicine Market Outlook, By Research institutes (2016-2026) (US $MN)
Table 52 North America Nuclear Medicine Market Outlook, By Hospitals and diagnostic centers (2016-2026) (US $MN)
Table 53 Europe Nuclear Medicine Market Outlook, By Country (2016-2026) (US $MN)
Table 54 Europe Nuclear Medicine Market Outlook, By Product (2016-2026) (US $MN)
Table 55 Europe Nuclear Medicine Market Outlook, By Therapeutic (2016-2026) (US $MN)
Table 56 Europe Nuclear Medicine Market Outlook, By Brachytherapy (2016-2026) (US $MN)
Table 57 Europe Nuclear Medicine Market Outlook, By Beta emitters (2016-2026) (US $MN)
Table 58 Europe Nuclear Medicine Market Outlook, By Alpha emitters (2016-2026) (US $MN)
Table 59 Europe Nuclear Medicine Market Outlook, By Diagnostic (2016-2026) (US $MN)
Table 60 Europe Nuclear Medicine Market Outlook, By PET (2016-2026) (US $MN)
Table 61 Europe Nuclear Medicine Market Outlook, By SPECT (2016-2026) (US $MN)
Table 62 Europe Nuclear Medicine Market Outlook, By Application (2016-2026) (US $MN)
Table 63 Europe Nuclear Medicine Market Outlook, By Therapeutic (2016-2026) (US $MN)
Table 64 Europe Nuclear Medicine Market Outlook, By Endocrine Tumors (2016-2026) (US $MN)
Table 65 Europe Nuclear Medicine Market Outlook, By Lymphoma (2016-2026) (US $MN)
Table 66 Europe Nuclear Medicine Market Outlook, By Bone Metastasis (2016-2026) (US $MN)
Table 67 Europe Nuclear Medicine Market Outlook, By Thyroid (2016-2026) (US $MN)
Table 68 Europe Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2016-2026) (US $MN)
Table 69 Europe Nuclear Medicine Market Outlook, By Diagnostic (2016-2026) (US $MN)
Table 70 Europe Nuclear Medicine Market Outlook, By Thyroid (2016-2026) (US $MN)
Table 71 Europe Nuclear Medicine Market Outlook, By Neurology (2016-2026) (US $MN)
Table 72 Europe Nuclear Medicine Market Outlook, By Lymphoma (2016-2026) (US $MN)
Table 73 Europe Nuclear Medicine Market Outlook, By Cardiology (2016-2026) (US $MN)
Table 74 Europe Nuclear Medicine Market Outlook, By Oncology (2016-2026) (US $MN)
Table 75 Europe Nuclear Medicine Market Outlook, By Other Diagnostics (2016-2026) (US $MN)
Table 76 Europe Nuclear Medicine Market Outlook, By End User (2016-2026) (US $MN)
Table 77 Europe Nuclear Medicine Market Outlook, By Research institutes (2016-2026) (US $MN)
Table 78 Europe Nuclear Medicine Market Outlook, By Hospitals and diagnostic centers (2016-2026) (US $MN)
Table 79 Asia Pacific Nuclear Medicine Market Outlook, By Country (2016-2026) (US $MN)
Table 80 Asia Pacific Nuclear Medicine Market Outlook, By Product (2016-2026) (US $MN)
Table 81 Asia Pacific Nuclear Medicine Market Outlook, By Therapeutic (2016-2026) (US $MN)
Table 82 Asia Pacific Nuclear Medicine Market Outlook, By Brachytherapy (2016-2026) (US $MN)
Table 83 Asia Pacific Nuclear Medicine Market Outlook, By Beta emitters (2016-2026) (US $MN)
Table 84 Asia Pacific Nuclear Medicine Market Outlook, By Alpha emitters (2016-2026) (US $MN)
Table 85 Asia Pacific Nuclear Medicine Market Outlook, By Diagnostic (2016-2026) (US $MN)
Table 86 Asia Pacific Nuclear Medicine Market Outlook, By PET (2016-2026) (US $MN)
Table 87 Asia Pacific Nuclear Medicine Market Outlook, By SPECT (2016-2026) (US $MN)
Table 88 Asia Pacific Nuclear Medicine Market Outlook, By Application (2016-2026) (US $MN)
Table 89 Asia Pacific Nuclear Medicine Market Outlook, By Therapeutic (2016-2026) (US $MN)
Table 90 Asia Pacific Nuclear Medicine Market Outlook, By Endocrine Tumors (2016-2026) (US $MN)
Table 91 Asia Pacific Nuclear Medicine Market Outlook, By Lymphoma (2016-2026) (US $MN)
Table 92 Asia Pacific Nuclear Medicine Market Outlook, By Bone Metastasis (2016-2026) (US $MN)
Table 93 Asia Pacific Nuclear Medicine Market Outlook, By Thyroid (2016-2026) (US $MN)
Table 94 Asia Pacific Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2016-2026) (US $MN)
Table 95 Asia Pacific Nuclear Medicine Market Outlook, By Diagnostic (2016-2026) (US $MN)
Table 96 Asia Pacific Nuclear Medicine Market Outlook, By Thyroid (2016-2026) (US $MN)
Table 97 Asia Pacific Nuclear Medicine Market Outlook, By Neurology (2016-2026) (US $MN)
Table 98 Asia Pacific Nuclear Medicine Market Outlook, By Lymphoma (2016-2026) (US $MN)
Table 99 Asia Pacific Nuclear Medicine Market Outlook, By Cardiology (2016-2026) (US $MN)
Table 100 Asia Pacific Nuclear Medicine Market Outlook, By Oncology (2016-2026) (US $MN)
Table 101 Asia Pacific Nuclear Medicine Market Outlook, By Other Diagnostics (2016-2026) (US $MN)
Table 102 Asia Pacific Nuclear Medicine Market Outlook, By End User (2016-2026) (US $MN)
Table 103 Asia Pacific Nuclear Medicine Market Outlook, By Research institutes (2016-2026) (US $MN)
Table 104 Asia Pacific Nuclear Medicine Market Outlook, By Hospitals and diagnostic centers (2016-2026) (US $MN)
Table 105 South America Nuclear Medicine Market Outlook, By Country (2016-2026) (US $MN)
Table 106 South America Nuclear Medicine Market Outlook, By Product (2016-2026) (US $MN)
Table 107 South America Nuclear Medicine Market Outlook, By Therapeutic (2016-2026) (US $MN)
Table 108 South America Nuclear Medicine Market Outlook, By Brachytherapy (2016-2026) (US $MN)
Table 109 South America Nuclear Medicine Market Outlook, By Beta emitters (2016-2026) (US $MN)
Table 110 South America Nuclear Medicine Market Outlook, By Alpha emitters (2016-2026) (US $MN)
Table 111 South America Nuclear Medicine Market Outlook, By Diagnostic (2016-2026) (US $MN)
Table 112 South America Nuclear Medicine Market Outlook, By PET (2016-2026) (US $MN)
Table 113 South America Nuclear Medicine Market Outlook, By SPECT (2016-2026) (US $MN)
Table 114 South America Nuclear Medicine Market Outlook, By Application (2016-2026) (US $MN)
Table 115 South America Nuclear Medicine Market Outlook, By Therapeutic (2016-2026) (US $MN)
Table 116 South America Nuclear Medicine Market Outlook, By Endocrine Tumors (2016-2026) (US $MN)
Table 117 South America Nuclear Medicine Market Outlook, By Lymphoma (2016-2026) (US $MN)
Table 118 South America Nuclear Medicine Market Outlook, By Bone Metastasis (2016-2026) (US $MN)
Table 119 South America Nuclear Medicine Market Outlook, By Thyroid (2016-2026) (US $MN)
Table 120 South America Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2016-2026) (US $MN)
Table 121 South America Nuclear Medicine Market Outlook, By Diagnostic (2016-2026) (US $MN)
Table 122 South America Nuclear Medicine Market Outlook, By Thyroid (2016-2026) (US $MN)
Table 123 South America Nuclear Medicine Market Outlook, By Neurology (2016-2026) (US $MN)
Table 124 South America Nuclear Medicine Market Outlook, By Lymphoma (2016-2026) (US $MN)
Table 125 South America Nuclear Medicine Market Outlook, By Cardiology (2016-2026) (US $MN)
Table 126 South America Nuclear Medicine Market Outlook, By Oncology (2016-2026) (US $MN)
Table 127 South America Nuclear Medicine Market Outlook, By Other Diagnostics (2016-2026) (US $MN)
Table 128 South America Nuclear Medicine Market Outlook, By End User (2016-2026) (US $MN)
Table 129 South America Nuclear Medicine Market Outlook, By Research institutes (2016-2026) (US $MN)
Table 130 South America Nuclear Medicine Market Outlook, By Hospitals and diagnostic centers (2016-2026) (US $MN)
Table 131 Middle East & Africa Nuclear Medicine Market Outlook, By Country (2016-2026) (US $MN)
Table 132 Middle East & Africa Nuclear Medicine Market Outlook, By Product (2016-2026) (US $MN)
Table 133 Middle East & Africa Nuclear Medicine Market Outlook, By Therapeutic (2016-2026) (US $MN)
Table 134 Middle East & Africa Nuclear Medicine Market Outlook, By Brachytherapy (2016-2026) (US $MN)
Table 135 Middle East & Africa Nuclear Medicine Market Outlook, By Beta emitters (2016-2026) (US $MN)
Table 136 Middle East & Africa Nuclear Medicine Market Outlook, By Alpha emitters (2016-2026) (US $MN)
Table 137 Middle East & Africa Nuclear Medicine Market Outlook, By Diagnostic (2016-2026) (US $MN)
Table 138 Middle East & Africa Nuclear Medicine Market Outlook, By PET (2016-2026) (US $MN)
Table 139 Middle East & Africa Nuclear Medicine Market Outlook, By SPECT (2016-2026) (US $MN)
Table 140 Middle East & Africa Nuclear Medicine Market Outlook, By Application (2016-2026) (US $MN)
Table 141 Middle East & Africa Nuclear Medicine Market Outlook, By Therapeutic (2016-2026) (US $MN)
Table 142 Middle East & Africa Nuclear Medicine Market Outlook, By Endocrine Tumors (2016-2026) (US $MN)
Table 143 Middle East & Africa Nuclear Medicine Market Outlook, By Lymphoma (2016-2026) (US $MN)
Table 144 Middle East & Africa Nuclear Medicine Market Outlook, By Bone Metastasis (2016-2026) (US $MN)
Table 145 Middle East & Africa Nuclear Medicine Market Outlook, By Thyroid (2016-2026) (US $MN)
Table 146 Middle East & Africa Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2016-2026) (US $MN)
Table 147 Middle East & Africa Nuclear Medicine Market Outlook, By Diagnostic (2016-2026) (US $MN)
Table 148 Middle East & Africa Nuclear Medicine Market Outlook, By Thyroid (2016-2026) (US $MN)
Table 149 Middle East & Africa Nuclear Medicine Market Outlook, By Neurology (2016-2026) (US $MN)
Table 150 Middle East & Africa Nuclear Medicine Market Outlook, By Lymphoma (2016-2026) (US $MN)
Table 151 Middle East & Africa Nuclear Medicine Market Outlook, By Cardiology (2016-2026) (US $MN)
Table 152 Middle East & Africa Nuclear Medicine Market Outlook, By Oncology (2016-2026) (US $MN)
Table 153 Middle East & Africa Nuclear Medicine Market Outlook, By Other Diagnostics (2016-2026) (US $MN)
Table 154 Middle East & Africa Nuclear Medicine Market Outlook, By End User (2016-2026) (US $MN)
Table 155 Middle East & Africa Nuclear Medicine Market Outlook, By Research institutes (2016-2026) (US $MN)
Table 156 Middle East & Africa Nuclear Medicine Market Outlook, By Hospitals and diagnostic centers (2016-2026) (US $MN)